Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Melissa A. Deri"'
Publikováno v:
Current Radiopharmaceuticals. 16:95-106
Abstract: In recent years, there has been an increased interest in 44Ti/44Sc generators as an onsite source of 44Sc for medical applications without needing a proximal cyclotron. The relatively short half-life (3.97 hours) and high positron branching
Publikováno v:
Bioconjugate chemistry. 32(7)
The continual development of radiopharmaceutical agents for the field of nuclear medicine is integral to promoting the necessity of personalized medicine. One way to greatly expand the selection of radiopharmaceuticals available is to broaden the ran
Autor:
Jannatul Ferdous, Jason S. Lewis, Lynn C. Francesconi, Suzanne E. Lapi, Michael D. Phipps, Shelbie J. Cingoranelli, Melissa A. Deri, N. V. S. Dinesh K. Bhupathiraju
Publikováno v:
Nuclear Medicine and Biology. :S91-S92
Autor:
N. V. S. Dinesh K. Bhupathiraju, Shashikanth Ponnala, Ali Younes, Lynn C. Francesconi, Kathryn M. Tully, Huseyin T. Cicek, Jason S. Lewis, John W. Babich, Jafar Sunga Ali, Minhua Cao, Melissa A. Deri, Charles Michael Drain
Publikováno v:
Org Biomol Chem
The bifunctional ligand p-SCN-Bn-HOPO, which has four 1,2-hydroxypyridinone groups on a spermine backbone with an isothiocyanate linker, has been shown to be an efficient and stable chelator for Zr(IV) and, more importantly, the radioisotope (89)Zr f
Publikováno v:
Journal of College Science Teaching.
Publikováno v:
ACS Symposium Series ISBN: 9780841232723
ACS Symposium Series
ACS Symposium Series
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96b7214cc12fb3415d5b04779e4c0c5e
https://doi.org/10.1021/bk-2017-1270.ch005
https://doi.org/10.1021/bk-2017-1270.ch005
Autor:
Melissa A. Deri, Gabor Pohl, Jason S. Lewis, Shashikanth Ponnala, J. J. Dannenberg, Brian M. Zeglis, Lynn C. Francesconi
Publikováno v:
Journal of Medicinal Chemistry
Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) imaging because its physical half-life (78.41 h) matches the biological half-life of IgG antibodies. Desferrioxamine (DFO) is currently the preferred chel
Publikováno v:
Nuclear Medicine and Biology. :S33
Autor:
Melissa A. Deri, J. Hatcher, Lynn C. Francesconi, D. Demoin, Jason S. Lewis, Kathryn M. Tully
Publikováno v:
Nuclear Medicine and Biology. :S49